HomeZYME • NASDAQ
Zymeworks Inc
$10.57
Mar 28, 12:32:44 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$10.30
Day range
$10.34 - $10.57
Year range
$6.02 - $13.14
Market cap
745.91M USD
Avg Volume
585.73K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
16.93M-95.79%
Operating expense
14.84M-53.24%
Net income
-14.48M-104.68%
Net profit margin
-85.56-211.29%
Earnings per share
-0.20-104.30%
EBITDA
-21.61M-106.77%
Effective tax rate
24.59%—
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
374.33M-23.95%
Total assets
580.88M-10.46%
Total liabilities
116.07M-25.48%
Total equity
464.81M—
Shares outstanding
70.57M—
Price to book
1.55—
Return on assets
-10.18%—
Return on capital
-12.28%—
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-14.48M-104.68%
Cash from operations
13.95M-95.74%
Cash from investing
-1.34M93.94%
Cash from financing
50.61M13,524.67%
Net change in cash
63.22M-79.26%
Free cash flow
13.60M-93.69%
About
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Founded
2003
Employees
275
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu